Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — OncoCyte — Investor Presentation (September 2019)
15 slides from Insight Molecular Diagnostics's investor presentation, Sep 5, 2019
Slide 1: September 2019
September 2019
Slide 2: Forward Looking Statements
Forward Looking Statements 2 Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are foWelgooke statements. These statements include those pertaini
Slide 3: We are building a global oncology content company
IY We are building a global oncology content company with a portfolio of high value molecular tests, that help physicians and patients make informed care decisions to improve outcomes, reduce overall cost of care and drive significant returns for our shareholders. Oncocyte"
Slide 4: Potential Growth Vectors
Potential Growth Vectors Core Asset Vandation and intate Development Ce egencont Explore opportunities Partnership = Opportunities improve erst and Mergers and ora a CQUISITIONS creating lung vertical Aas Initial sales in key states Leverage biobank for access to methylation and cfDNA applications H
Slide 5: Opportunity Selection Criteria
Opportunity Selection Criteria SS ° High degree of scientific confidence * Serve critical decision points in clinical oncology (focus on lung) * Reimbursed content, or developing content with market predicate ° Area of high unmet clinical need ° High margin « LDT US, potential to “kit” for ROW Oncoc
Slide 6: Razor Acquisition Expands Cancer Diagnostic Continuum
Razor Acquisition Expands Cancer Diagnostic Continuum Diagnosis of Cancer Genetic Pre- Disposition jiagnostic Stage of Care Diagnosis OncoCyte DetermaVu Post LDCT/pre biopsy Post-Diagnosis Treatment Selection Treatment Stratification Therapy Monitoring and Recurrence Detection ”AZORCENOMICS Razor Te
Slide 7: Combined DetermaVu and Razor Answer Critical Questions
Combined DetermaVu and Razor Answer Critical Questions and Establish Oncocyte as the Leader 5 in Early Stage Lung Content Determa@®” = RAZORGENOMICS tuna = Rage! Malignant Confirmatory fit) } & OL mn sonan so Lecce nodule \ Biopsy i /] eo 8 Clear Average cost of biopsy and complications ~$15,000 Sna
Slide 8: Founder Biographies
Founder Biographies David M. Jablons, MD Founder Professor David Jablons, MD is an internationally recognized leader in the fields of Surgical Thoracic Oncology and in Thoracic Oncology Research. He is the founder and Chief of the Thoracic Oncology Program at UCSF, as well as the Chief of the Thorac
Slide 9: Razor Test Dramatically Reduces Mortality Rate for Early Stage Patients
Razor Test Dramatically Reduces Mortality 9 Rate for Early Stage Patients * The ~40,000 patients diagnosed annually in von potent ac the US with “curable early stage” lung gooceoe tones hHHESSESdS=SSoS et chemo cancer face 30-50% mortality. * In independent, blinded, international trials of over 150
Slide 10: Published Research
; Published Research Landmark publications in 2012 with subsequent data published in 2018 supporting clinical utility positions Razor Genomics as a First Mover Appractical molecular assay to predict survival in resected ‘Adjuvant Chemotherapy Guided by Molecular non-squamous,non-small-ellng cancer:
Slide 11: Razor Test Significantly Reduces Mortality for Stage I Patients
Razor Test Significantly Reduces Mortality for : Stage | Patients Razor Test No Chemo 25% 49% 5-year Highiisk: Survival 100% patients get Razor Test 75% 94% 5-year Low & Intermediate Survival Risk * Few Stage | patients are administered chemotherapy + Over a quarter could benefit from chemotherapy *
Slide 12: First Mover Advantage in a Significant Market Opportunity
First Mover Advantage in a Significant ; Market Opportunity Market Overview Reimbursement Process +» =40,000 Stage | or Il non-squamous NSCLC + Received proposed positive LCD in August! resections in the US annuall a + Similar Prognostic Gene Expression panels are * Increasing Stage | population wit
Slide 13: Establishing Strong Barriers to Entry
Establishing Strong Barriers to Entry ee Initiating Key Clinical Marketing Study Test is Patent Protected Razor Genomics' planned prospective + Patents already issued in all major markets in randomized clinical trial to dramatically US, Europe & Asia accelerate adoption * Test also protected by trad
Slide 14: Standard Workflow Allows for Rapid Global Launch
Standard Workflow Allows for Rapid Global » Launch on Widely Adopted Platform Quantitative Prognostic MRNA, Real-Time ‘Algorithm Resected, Non ‘Small Cell Lung pmaction PCR mRN Identification of High- nee. ed — > ee > BD (NSCLC) FEPE treatment decision ‘Sample as cONA Reverse Transcription Test desi
Slide 15: Razor Genomics Acquisition Summary
Razor Genomics Acquisition Summary 2 * Razor Risk Stratification Test significantly reduces mortality! * The test has been validated and published in peer review journals » Recommendations to change staging protocol published in Jul'18 » Recent CMS Positive Coverage Decision indicative of the need f